PMID- 34897575
OWN - NLM
STAT- MEDLINE
DCOM- 20220218
LR  - 20240405
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 82
IP  - 1
DP  - 2022 Jan
TI  - Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis.
PG  - 55-62
LID - 10.1007/s40265-021-01650-7 [doi]
AB  - Ofatumumab (Kesimpta((R))) is a fully human anti-CD20 monoclonal antibody that can 
      be self-administered by patients and is approved in several countries worldwide 
      for the treatment of relapsing forms of multiple sclerosis (MS). In two identical 
      phase III trials in adults with relapsing forms of MS, subcutaneous ofatumumab 
      was more effective than oral teriflunomide in reducing the annualized relapse 
      rate, as well as reducing MRI-detected lesion activity and limiting worsening of 
      disability. Ofatumumab had a generally manageable tolerability profile; the most 
      common adverse events (AEs) included nasopharyngitis, headache, upper respiratory 
      tract infections and urinary tract infections. AEs of special interest (AESIs) 
      included infections and injection-related reactions, which were generally 
      manageable. There was no apparent association between changes in immunoglobulin G 
      or M levels and the risk of serious infections after 3.5 years of ofatumumab 
      treatment. Thus, ofatumumab is a convenient treatment option that is effective 
      and has a generally manageable tolerability profile in adults with relapsing 
      forms of MS.
CI  - (c) 2021. Springer Nature.
FAU - Kang, Connie
AU  - Kang C
AD  - Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. 
      demail@springer.com.
FAU - Blair, Hannah A
AU  - Blair HA
AD  - Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - M95KG522R0 (ofatumumab)
SB  - IM
EIN - Drugs. 2021 Dec 29;:. PMID: 34964925
MH  - Antibodies, Monoclonal, Humanized/adverse effects/pharmacology/*therapeutic use
MH  - Antineoplastic Agents/adverse effects/pharmacology/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Multiple Sclerosis, Relapsing-Remitting/*drug therapy
PMC - PMC8748350
OAB - MS is an incurable disease that affects  approximately  2.8 million people worldwide. Limiting 
      the progression of disability associated with this disease is crucial, and 
      treatments such as teriflunomide or monoclonal antibodies can prevent the 
      relapses which define MS. Ofatumumab (Kesimpta((R))), a monoclonal antibody, works 
      by reducing the level of B cells which contribute to the development and 
      progression of MS. Ofatumumab is approved in several countries worldwide to treat 
      adults with certain relapsing forms of MS. It is administered by subcutaneous 
      injection once per month and is the first therapy of its kind that patients can 
      self-inject at home. In clinical trials, ofatumumab was more effective than 
      teriflunomide in reducing the annual relapse rate, as well as slowing both the 
      progression of disability and formation of new MS lesions in the brain. 
      Ofatumumab had a generally manageable tolerability profile, although treatment 
      resulted in infections and injection-related reactions; these were generally 
      manageable with treatment. Thus, ofatumumab is an effective and convenient 
      treatment option, with a generally manageable tolerability profile, in adults 
      with relapsing forms of MS.
OABL- eng
COIS- Connie Kang and Hannah Blair are salaried employees of Adis International 
      Ltd/Springer Nature, and declare no relevant conflicts of interest. All authors 
      contributed to the review and are responsible for the article content.
EDAT- 2021/12/14 06:00
MHDA- 2022/02/19 06:00
PMCR- 2021/12/13
CRDT- 2021/12/13 13:31
PHST- 2021/12/14 06:00 [pubmed]
PHST- 2022/02/19 06:00 [medline]
PHST- 2021/12/13 13:31 [entrez]
PHST- 2021/12/13 00:00 [pmc-release]
AID - 10.1007/s40265-021-01650-7 [pii]
AID - 1650 [pii]
AID - 10.1007/s40265-021-01650-7 [doi]
PST - ppublish
SO  - Drugs. 2022 Jan;82(1):55-62. doi: 10.1007/s40265-021-01650-7.